Overview:
Endocrine therapy (ET) is standard-of care for most estrogen receptor-positive (ER+) metastatic breast cancers (MBC), but nearly all patients will develop therapeutic resistance. Mechanisms of resistance include activation of alternative signaling pathways, which may be addressed by combinatorial strategies, as well as mutation of the estrogen receptor gene, ESR1. Next generation oral selective estrogen receptor degraders (SERDs) have demonstrated activity in ESR1-mutated ER+/HER2- MBC, and have begun to enter the clinic based on pivotal phase 3 data. Other novel endocrine agents in development include new selective estrogen receptor modulators (SERMs), complete estrogen receptor antagonists (CERANs), ER proteolysis targeting chimeras (PROTACs), oral covalent ERα antagonists (SERCAs), and selective androgen receptor modulators (SARMs).
This Medical Crossfire® satellite symposium will be held ancillary to the 2024 annual breast cancer meeting held in San Antonio, Texas, and will provide a forum for recognized experts in the treatment of breast cancer to discuss the latest strategies for managing ER+/HER2- MBC, including new and emerging agents targeting the ER. A mix of didactic presentations with case-based panel discussions will allow in-depth review of real-world patient scenarios integrated with relevant clinical evidence. Discussion topics will include biomarker testing and the dynamics of ESR1 mutation, individualized treatment planning and the evidence-based integration of next-generation oral SERDs, emerging data with investigational ER-targeted agents, and best practices for the management of adverse events.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Examine biomarker testing in diagnostic approaches to select optimal individualized HR+/HER2- mBC treatment options
- Evaluate data supporting current and emerging agents for HR+/HER2- mBC and implement evidence-based individualized treatment into clinical practice
- Develop shared decision-making strategies in HR+/HER2- mBC clinical practice to effectively manage AEs and ensure treatment adherence
Aditya Bardia, MD, MPH
Director, Breast Cancer Clinical and Research Programs
Assistant Chief of Translational Research, Division of Medical Oncology
University of California, Los Angeles
Los Angeles, CA
Heather McArthur, MD, MPH
Clinical Director, Breast Cancer Program
The University of Texas Southwestern
Medical Center
Dallas, TX
Sonya Reid, MD, MPH
Assistant Professor of Medicine, Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, TN
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn a maximum of MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.